1-2 of 2
Pamela B. Conley, Ph.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Crowther Mark, MD, Mathur Vandana, MD, Kitt Michael, MD, Lu Genmin, PhD, Pamela B. Conley, Ph.D., Hollenbach Stanley, JD, Janice Castillo, Athiwat Hutchaleelaha, Ph.D., Mark Karbarz, Ph.D., Joyce P. Lin, Lee Barron, PhD, Sandra Russell, R.N, Gallia G. Levy, MD, PhD, Stuart Connolly, M.D., John T. Curnutte, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3636.
https://doi.org/10.1182/blood.V122.21.3636.3636
Published: 2013
Journal Articles

Specific Inhibition of Syk Is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin’s Lymphoma Cell Lines without Concomitant Inhibition of JAK.

Greg Coffey, Ph.D., Peng Luan, Ph.D., Suzanne Delaney, Ph.D., Anjali Pandey, Ph.D., Zhaozhong Jia, Ph.D., Qing Xu, Ph.D., Shawn Bauer, Ph.D., Yonghong Song, Ph.D., Pamela B. Conley, Ph.D., David Phillips, Ph.D., Uma Sinha, Ph.D.
Journal: Blood
Blood (2008) 112 (11): 1794.
https://doi.org/10.1182/blood.V112.11.1794.1794
Published: 2008